You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 6,811,779

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,811,779

Title:	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
Abstract:	The invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and radiation. In addition, the invention provides a method of reducing tumor growth in a mammal comprising treating the mammal with an effective amount of a combination of a VEGF receptor antagonist and a chemotherapeutic agent.
Inventor(s):	Rockwell; Patricia (West Redding, CT), Goldstein; Neil I. (Maplewood, NJ)
Assignee:	ImClone Systems Incorporated (New York, NY)
Application Number:	09/798,689
Patent Claims:	1. A method for reducing tumor growth in a mammal in need thereof comprising treating the mammal with an effective amount of a combination of a monoclonal antibody which specifically binds to an extracellular domain of a VEGF receptor and radiation. 2. A method according to claim 1 wherein the mammal is a human. 3. A method according to claim 1 wherein the monoclonal antibody is administered before radiation. 4. A method according to claim 1 wherein the monoclonal antibody is administered during radiation. 5. A method according to claim 1 wherein the monoclonal antibody is admimstcrcd after radiation. 6. A method according to claim 1 wherein the monoclonal antibody is administered before and during radiation. 7. A method according to claim 1 wherein the monoclonal antibody is administered during and after radiation. 8. A method according to claim 1 wherein the monoclonal antibody is administered before and after radiation. 9. A method according to claim 1 wherein the monoclonal antibody is administered before, during, and after radiation. 10. A method according to claim 1 wherein the source of the radiation is external to the mammal. 11. A method according to claim 1 wherein the source of radiation is internal to the mammal. 12. A method according to claim 1 wherein the antibody is c-p1C11. 13. A method for reducing tumor growth in a mammal in need thereof comprising treating the mammal with an effective amount of a combination of a monoclonal antibody which specifically binds to an extracellular domain of a VEGF receptor and a chemotherapeutic agent. 14. A method according to claim 13 wherein the chemotherapeutic agent is not conjugated to the VEGF receptor monoclonal antibody. 15. A method according to claim 13 wherein the mammal is a human. 16. A method according to claim 13 wherein the monoclonal antibody is administered before treatment with the chemotherapeutic agent. 17. A method according to claim 13 wherein the monoclonal antibody is administered during treatment with the chemotherapeutic agent. 18. A method according to claim 13 wherein the monoclonal antibody is administered after treatment with the chemotherapeutic agent. 19. A method according to claim 13 wherein the monoclonal antibody is administered before and during treatment with the chemotherapeutic agent. 20. A method according to claim 13 wherein the monoclonal antibody is administered during and after treatment with the chemotherapeutic agent. 21. A method according to claim 13 wherein the monoclonal antibody is administered before and after treatment with the chemotherapeutic agent. 22. A method according to claim 13 wherein the monoclonal antibody is administered before, during, and after treatment with the chemotherapeutic agent. 23. A method according to claim 13 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, dicarbazine, dactinomycin, mechlorethamine, streptozocin, cyclophosphamide, carmustine, lomustine, doxorubicin, daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinbiastine, vincristine, bleomycin, paclitaxel, docetaxel, aldesleukin, asparaginase, busulfan, carboplatin, cladribine, dacarbazine, floxuridine, fludarabine, hydroxyurea, ifosfamide, interferon alpha, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, plicamycin, streptozocin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil, taxol, an additional growth factor receptor antagonist and combinations thereof. 24. A method according to claim 13 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, doxorubicin, taxol and combinations thereof. 25. A method according to claim 13 wherein the antibody is c-p1C11. 26. A method according to claim 23 wherein the additional antagonist is a small molecule. 27. A method according to claim 13 further comprising treating the mammal with radiation.

Details for Patent 6,811,779

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2014-10-20
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992	⤷ Try a Trial	2014-10-20
Servier Pharmaceuticals Llc	ONCASPAR	pegaspargase	Injection	103411	02/01/1994	⤷ Try a Trial	2014-10-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.